These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 16481638)
1. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Gogas H; Ioannovich J; Dafni U; Stavropoulou-Giokas C; Frangia K; Tsoutsos D; Panagiotou P; Polyzos A; Papadopoulos O; Stratigos A; Markopoulos C; Bafaloukos D; Pectasides D; Fountzilas G; Kirkwood JM N Engl J Med; 2006 Feb; 354(7):709-18. PubMed ID: 16481638 [TBL] [Abstract][Full Text] [Related]
2. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM; J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353 [TBL] [Abstract][Full Text] [Related]
3. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998 [TBL] [Abstract][Full Text] [Related]
4. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564 [TBL] [Abstract][Full Text] [Related]
5. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b. Fluck M; Kamanabrou D; Lippold A; Reitz M; Atzpodien J Cancer Biother Radiopharm; 2005 Jun; 20(3):280-9. PubMed ID: 15989473 [TBL] [Abstract][Full Text] [Related]
6. Autoimmunity and immunotherapy for cancer. Koon H; Atkins M N Engl J Med; 2006 Feb; 354(7):758-60. PubMed ID: 16481646 [No Abstract] [Full Text] [Related]
7. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196 [TBL] [Abstract][Full Text] [Related]
8. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Tarhini AA; Shin D; Lee SJ; Stuckert J; Sander CA; Kirkwood JM Melanoma Res; 2014 Apr; 24(2):150-7. PubMed ID: 24509407 [TBL] [Abstract][Full Text] [Related]
9. Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort. Maire C; Vercambre-Darras S; Devos P; D'Herbomez M; Dubucquoi S; Mortier L J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):92-6. PubMed ID: 22145691 [TBL] [Abstract][Full Text] [Related]
10. Low-dose adjuvant interferon for stage III malignant melanoma. Inman JL; Russell GB; Savage P; Levine EA Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352 [TBL] [Abstract][Full Text] [Related]
11. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686 [TBL] [Abstract][Full Text] [Related]
13. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D; Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. Pectasides D; Dafni U; Bafaloukos D; Skarlos D; Polyzos A; Tsoutsos D; Kalofonos H; Fountzilas G; Panagiotou P; Kokkalis G; Papadopoulos O; Castana O; Papadopoulos S; Stavrinidis E; Vourli G; Ioannovich J; Gogas H J Clin Oncol; 2009 Feb; 27(6):939-44. PubMed ID: 19139440 [TBL] [Abstract][Full Text] [Related]
16. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805 [TBL] [Abstract][Full Text] [Related]
17. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Kirkwood JM; Strawderman MH; Ernstoff MS; Smith TJ; Borden EC; Blum RH J Clin Oncol; 1996 Jan; 14(1):7-17. PubMed ID: 8558223 [TBL] [Abstract][Full Text] [Related]
18. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U; Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Bajetta E Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604 [No Abstract] [Full Text] [Related]
20. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]